Launch Excellence 2035. Winning in an era of exponential change.

The medicine has not changed. The conditions for its success have.

The pharmaceutical industry is being reshaped at its foundations. Artificial intelligence, genomics and more precise diagnostics are converging with pressure on affordability, new ways of delivering care and a changing role for patients. Together these forces challenge more than how the industry works. They challenge what it can discover, whom it can treat, and how scientific progress translates into real-world patient outcomes and commercial value.

The purpose of this exploration is not to identify the most likely future. It is to reveal the choices a launch strategy built only around today’s market could miss.

The worlds diverge on authority and on money.

Some forces are already in motion and every future contains them; their pace, reach and commercial consequences are what remain open. Ten uncertainties shape the U.S. launch environment in 2035, consolidated from the wider set surfaced in the research and assessed for their impact on launch and how open they remain. Two frame the worlds: one concerns authority, the other concerns money.

Four worlds. What would winning require?

Algorithmic Order

System-governed · Paid for outcomes

The medicine works. Its place in the system is another question.

An alert sets the care journey in motion: tests, treatment, monitoring, and follow-up. Institutional pathways coordinate the steps and set the expected treatment sequence; clinicians must justify exceptions.

A material share of medicine payment depends on verified results after treatment. Therapies can reach many patients quickly, yet their place in the pathway is continually reassessed. Patients have less to arrange, and less room to choose.

The launch priority. Earn and retain a pathway position. Align evidence, delivery, and responsibility for the result.

The Waiting Room

System-governed · Paid by price and volume

The patient has been found. The money has not.

Earlier diagnosis reveals more treatable need than budgets and capacity can absorb. A patient qualifies clinically for a therapy, but not for her plan’s funded tier. Her sister, covered by another employer, receives it.

Payment stays tied to units at negotiated prices. Companies compete to make effective care affordable at scale through better patient selection, lower-cost alternatives, and simpler delivery. Knowing sooner does not guarantee access.

The launch priority. Demonstrate who benefits most. Design price and delivery together to make effective treatment affordable at scale.

Precision Islands

Distributed · Paid for outcomes

Prevention is organized. Treatment remains a personal choice.

A nurse calls before the next appointment because home readings have changed. Patient and physician choose a treatment that fits daily life. Competing networks connect prevention, treatment, and follow-up while preserving treatment choice.

Networks tie a material share of medicine payment to verified results. Coverage, resources, and participation shape access. Two people with the same condition can receive very different care because only one belongs to the network.

The launch priority. Build partnerships that travel. Test whether the evidence, support, and economics work across different networks.

Many Doors

Distributed · Paid by price and volume

Care remains episodic. The sources of influence multiply.

A patient has three recommendations and no prescription. Her physician, payer, and personal AI adviser each hold part of the picture. Membership services and manufacturer channels open new routes, but patients often connect the steps themselves.

Care remains episodic, and medicines are paid for through units at agreed net or cash prices. Patients and clinicians retain treatment choice. More information creates options without necessarily connecting advice, funding, and treatment.

The launch priority. Establish value across clinical, patient, and payer decisions. Connect the routes that turn advice into treatment.

Seven no-regret moves. Useful in every world.

Recurring disciplines that strengthen launch readiness no matter which future materializes. Build common foundations, then test world-specific options before committing at scale.

1. Rehearse, monitor, and adapt. Test plans across worlds; link signals to an accountable response.
2. Build evidence that earns trust. Address meaningful benefit, patient subgroups, and uncertainty.
3. Build AEO and decision-system readiness. Start answer engine optimization with on-market products; audit product visibility and representation in patient-facing AI, including evidence, risks, and approval status.
4. Design access for affordable scale. Test price, delivery requirements, and reachable treatment together.
5. Build with patients, not only for them. Let treatment burden, preferences, and access barriers shape the proposition.
6. Choose ecosystem roles and partners. Agree what the company supplies and who is responsible for the rest.
7. Rehearse delivery and accountability. Test capacity and handoffs; assign decision rights and reuse the learning.

THRIVE Futures Architecture™. Scenario planning for decisions under deep uncertainty.

THRIVE Futures Architecture™ is our scenario planning methodology for decisions under deep uncertainty. It moves from what is given, the driving forces, to what is open, the critical uncertainties, to the two selected as axes, to the worlds those axes define, and then to the response for a specific decision-maker. The worlds are built so that a strategy or plan can be tested against each of them.

The public edition is written through the lens of launch leaders and the functions that support them. THRIVE’s Futures of Biopharma work extends to strategy, portfolios, care models and organizational capability. The extended research is shared selectively following a conversation.